| Drug Name |
Ziconotide acetate |
| Drug ID |
BADD_D02382 |
| Description |
Ziconotide (also known as SNX-111) is a neurotoxic peptide derived from the cone snail _Conus magus_ comprising 25 amino acids with three disulphide bonds.[A202835, L13389] Other such peptides, collectively termed conotoxins, exist, and some have shown efficacy in binding specific subsets of calcium channels; ziconotide is used in part because it can be synthesized without loss of proper bond formation or structural elements.[A202829, A202832] Ziconotide is used to manage severe chronic pain refractory to other methods, through its ability to inhibit N-type calcium channels involved in nociceptive signalling.[A202829, A202835, A202838, A202841, A202850, A202859, L13389]
Ziconotide was granted FDA approval on December 28, 2004 for marketing by TerSera therapeutics LLC. under the name Prialt.[L13389] To date, ziconotide is the only calcium channel blocking peptide approved for use by the FDA.[A202835] |
| Indications and Usage |
Ziconotide is indicated for the management of severe chronic pain in patients refractory to other treatments, and for whom intrathecal therapy is warranted.[L13389] |
| Marketing Status |
approved |
| ATC Code |
N02BG08 |
| DrugBank ID |
DB06283
|
| KEGG ID |
D08686
|
| MeSH ID |
C078452
|
| PubChem ID |
16129690
|
| TTD Drug ID |
D01NLB
|
| NDC Product Code |
70720-722; 70720-723; 32861-0007; 70720-720 |
| UNII |
T2I226K69M
|
| Synonyms |
ziconotide | CYS-LYS-GLY-LYS-GLY-ALA-LYS-CYS-SER-ARG-LEU-MET-TYR-ASP-CYS-CYS-THR-GLY-SER-CYS-ARG-SER-GLY-LYS-CYS-NH2 | omega-conotoxin MVIIA | omega-conotoxin M VIIA | omega-conopeptide MVIIA | leconotide | SNX 111 | SNX-111 | omega-conotoxin MVIIA, Conus magus | Prialt |
